Erythropoietin (EPO) is a polypeptide hormone that stimulates erythropoiesis by controlling the formation and maturation of erythroid progenitors. The availability of recombinant human erythropoietin (rHuEPO) has led to the development of sensitive and specific immunoassay methods for the measurement of serum EPO concentrations and these have been shown to be of value in the differential diagnosis of various haematological disorders.' Anaemia due to chronic renal failure results from deficient production of EPO by diseased kidneys.? The serum EPO concentrations usually seen in this group of patients are inappropriately low for their degree of anaemia.! Administration of rHuEPO has been shown to correct the anaemia in these patients and to improve their morbidity. However, it is an expensive form of treatment (between £3000 and £5000per patient year) and overdosage with EPO is a potential hazard with hypertension and thrombotic complications as important sideeffects." We report the serum EPO concentrations in 17 patients with chronic renal failure during their treatment with rHuEPO.
METHODS AND RESULTS
Seventeen patients on haemodialysis (9 men, 8 women) with a mean age of 45 years (range 25-66 years) and haemoglobin concentrations less than 9 g/dL were given human rHuEPO (EprexR; Cilag Ltd, High Wycombe, UK) either intravenously (four patients) or subcutaneously (13 patients). The mean dose was 126IU/kg/week (range 66-320) in divided doses up to three times a week post-dialysis. Full blood count, reticulocyte count and routine biochemistry tests were carried out at four-weekly intervals and serum ferritin, vitamin B 12 , PTH, aluminium and Correspondence: Dr R A Sherwood. serum and red cell folate concentrations were measured every 3 months. No patients had chronic infection or malignancy, conditions which have been reported to be associated with resistance to rHuEPO. 5 Erythropoietin was assayed in serum samples taken 48 h post dose, with a competitive binding disequilibrium radioimmunoassay (Incstar Ltd, Stillwater, MN, USA) which used rHuEPO for both tracer and standards. Within assay reproducibility was 5·40/0 (n= 10, mean 18'7 lUlL) and the between assay coefficient of variation was 7' 3% (n = 10); the minimum detectable concentration was 4·4IU/L. The reference range, 9'1-30'8 IU/L, was established by the manufacturers, from normal subjects without anaemia. Response to therapy was defined as an increase in haemoglobin concentration of 1 g/df.Zmonth.! Ten patients responded to treatment according to this criterion (Group 1); their mean haemoglobin concentration increased from 6'4 g/dL (SD 0'65) to 9'7 g/dL (SD 0,48) over a mean period of 16 weeks. The remaining seven patients (Group 2) responded poorly and had a mean haemoglobin of 7· 3 g/dL (SD i-09) after the same period (mean pre-treatment haemoglobin 6'2g/dL, SD 0'85). The mean serum EPO concentrations (lU/L) in the two groups differed significantly (P< O' 01 by Student's t-test): 58' 5 (SD 33' 9) for Group 1 and 20· 7 (SD 10· 6) for Group 2, as shown in Table 1 . The dose of rHuEPO (IU/kg/week) was significantly higher (P<O'OI) in Group 1 with a mean value of 148 (SD 72) when compared to Group 2 with a mean value of 94 (SD 11). The mean serum creatinine, phosphate, PTH, aluminium, ferritin, vitamin B I2 and folate concentrations of the two groups were not significantly different (P>0·05). Eight of the 10 patients in Group 1 had an elevated PTH whilst only three in Group 2 had a raised PTH. In these cases serum EPO measurements showed that the poor response was more likely to be due to inadequate serum EPO levels rather than hyperparathyroidism. No patient had aluminium toxicity.
There was no correlation between mean serum EPO concentration and the administered dose expressed as IU/kg/week (r=0'45, P>0'05) for all patients but a significant correlation was obtained if the 13 who received rHuEPO subcutaneously were considered separately (r= 0'81, P<0·05). Individual serum EPO and haemoglobin measurements were not correlated (r=O' 34, P>0'05), neither was there a significant correlation between the mean serum EPO and the change in haemoglobin for each patient in the time period studied (r=0'47, P>0·05). Unlike the dose relationships there was no difference in the significance of the correlation of mean serum EPO with change in haemoglobin if the four patients receiving IV rHuEPO were omitted (r=0'49, P>0·05). The range of serum EPO concentrations in patients in Group I was very wide (17-108 IU/L) with 8/10 having a mean serum EPO above the reference range. Only 1/7 patients in Group 2 had a mean EPO above the reference range (range 10'2-37'7 IU/L).
DISCUSSION
The results of this study show that serum EPO concentrations are useful in predicting and assessing the therapeutic response in patients receiving rHuEPO. The results clearly show that a serum EPO concentration within the reference range is insufficient to correct the anaemia and successful response is achieved when the serum EPO is significantly above this range. The reference range was determined from individuals without anaemia or renal dysfunction whose EPO secretion is sufficient to maintain a normal haemoglobin rather than increase it. The lack of a linear relationship between serum EPO concentrations and haemoglobin response reflected two factors; the mean serum EPO for an individual patient was calculated regardless of whether there were any dose changes within the time period involved and sensitivity to the hormone varies between patients. The normal practice of titrating the dose of EPO on a monthly basis until the haemoglobin concentration reaches 10-12 g/dL, whilst effective long-term, can be expensive and results in a delay in establishing the minimum effective dose. A pre-treatment EPO measurement may be useful in the differential diagnosis of the anaemia and in identifying the patients who do not require EPO. In patients receiving EPO, it may give some indication of the dose needed. Assay of serum EPO levels costs a fraction of the weekly cost of the drug to a single patient and allows a more rapid optimization of the treatment regimen.
